Thrombosis and Haemostasis 2023 Editors' Choice Papers

Christian Weber; Anne Rigby; Gregory Y. H. Lip

doi:10.1055/s-0043-1778032

Thrombosis and Haemostasis, Inhaltsverzeichnis

Thromb Haemost 2024; 124(01): 080-087
DOI: 10.1055/s-0043-1778032

Editors' Choice

Thrombosis and Haemostasis 2023 Editors' Choice Papers

Christian Weber

¹Institute for Cardiovascular Prevention (IPEK), LMU Munich, Munich, Germany

²German Centre for Cardiovascular Research (DZHK), partner site Munich Heart Alliance, Munich, Germany

³Department of Biochemistry, Cardiovascular Research Institute Maastricht (CARIM), Maastricht University Medical Centre, Maastricht, The Netherlands

,

Anne Rigby

¹Institute for Cardiovascular Prevention (IPEK), LMU Munich, Munich, Germany

,

Gregory Y. H. Lip

⁴Liverpool Centre for Cardiovascular Science at University of Liverpool, Liverpool John Moores University and Liverpool Heart and Chest Hospital, Liverpool, United Kingdom

⁵Department of Clinical Medicine, Aalborg University, Aalborg, Denmark

References
1 Galli M, Laborante R, Ortega-Paz L. et al. Factor XI inhibitors in early clinical trials: a meta-analysis. Thromb Haemost 2023; 123 (06) 576-584
2 Foulon-Pinto G, Lafuente-Lafuente C, Jourdi G. et al. Assessment of DOAC in GEriatrics (Adage Study): rivaroxaban/apixaban concentrations and thrombin generation profiles in NVAF very elderly patients. Thromb Haemost 2023; 123 (04) 402-414
3 Eikelboom JW, Weitz JI. Direct oral anticoagulants in the very elderly. Thromb Haemost 2023; 123 (04) 377-379
4 Grymonprez M, Petrovic M, De Backer TL, Steurbaut S, Lahousse L. The impact of polypharmacy on the effectiveness and safety of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Thromb Haemost 2023; (e-pub ahead of print).
5 Zheng Y, Li S, Liu X, Lip GYH, Guo L, Zhu W. Effect of oral anticoagulants in atrial fibrillation patients with polypharmacy: a meta-analysis. Thromb Haemost 2023; (e-pub ahead of print).
6 Romiti GF, Proietti M, Bonini N. et al; GLORIA-AF Investigators. Clinical complexity domains, anticoagulation, and outcomes in patients with atrial fibrillation: a report from the GLORIA-AF registry phase II and III. Thromb Haemost 2022; 122 (12) 2030-2041
7 Lip GYH. The ABC pathway: an integrated approach to improve AF management. Nat Rev Cardiol 2017; 14 (11) 627-628
8 Romiti GF, Pastori D, Rivera-Caravaca JM. et al. Adherence to the ‘Atrial Fibrillation Better Care’ pathway in patients with atrial fibrillation: impact on clinical outcomes-a systematic review and meta-analysis of 285,000 patients. Thromb Haemost 2022; 122 (03) 406-414
9 Romiti GF, Guo Y, Corica B, Proietti M, Zhang H, Lip GYH. mAF-App II trial investigators. Mobile health-technology-integrated care for atrial fibrillation: a win ratio analysis from the mAFA-II randomized clinical trial. Thromb Haemost 2023; 123 (11) 1042-1048
10 Corica B, Romiti GF, Proietti M. NOACs in atrial fibrillation patients with polypharmacy. Thromb Haemost 2023; (e-pub ahead of print).
11 Chao TF, Joung B, Takahashi Y. et al. 2021 focused update consensus guidelines of the Asia Pacific Heart Rhythm Society on stroke prevention in atrial fibrillation: executive summary. Thromb Haemost 2022; 122 (01) 20-47
12 Schenker C, Stalder O, Méan M. et al. Bleeding risk in elderly patients with venous thromboembolism who would have been excluded from anticoagulation trials. Thromb Haemost 2023; 123 (04) 427-437
13 Li Z, Xu W, Wang L. et al. Risk of bleeding in liver cirrhosis receiving direct oral anticoagulants: a systematic review and meta-analysis. Thromb Haemost 2023; 123 (11) 1072-1088
14 Iding AFJ, Kremers BMM, Pallares Robles A, Ten Cate H, Ten Cate-Hoek AJ. Residual venous obstruction as an indicator of clinical outcomes following deep vein thrombosis: a management study. Thromb Haemost 2023; 123 (08) 763-772
15 Becattini C, Agnelli G. Residual thrombosis: still relevant in the direct oral anticoagulant (DOAC) era?. Thromb Haemost 2023; 123 (08) 747-749
16 Ivany E, Lotto RR, Lip GYH, Lane DA. Managing uncertainty: physicians' decision making for stroke prevention for patients with atrial fibrillation and intracerebral hemorrhage. Thromb Haemost 2022; 122 (09) 1603-1611
17 Gorman J, Candeloro M, Schulman S. Anticoagulant management and outcomes in nontraumatic intracranial hemorrhage complicated by venous thromboembolism: a retrospective chart review. Thromb Haemost 2023; 123 (10) 966-975
18 Milling Jr TJ. The hard bargain of anticoagulation after intracranial hemorrhage, in the setting of venous thromboembolism: between a rock and a hard place. Thromb Haemost 2023; 123 (10) 976-977
19 Lasne D, Toussaint-Hacquard M, Delassasseigne C. et al. Factors influencing anti-Xa assays: a multicenter prospective study in critically ill and noncritically ill patients receiving unfractionated heparin. Thromb Haemost 2023; 123 (12) 1105-1115
20 Yoon D, Jeong HE, Choi S, Shin JY, Bang SM. Dynamic patterns and persistence of anticoagulation therapy in patients with venous thromboembolism in South Korea: a nationwide cohort study. Thromb Haemost 2023; (e-pub ahead of print).
21 Germini F, Chan NC. Patterns and persistence of anticoagulant use in the treatment of venous thromboembolism: insights from South Korea. Thromb Haemost 2023; (e-pub ahead of print).
22 Gorog DA, Gue YX, Chao TF. et al. Assessment and mitigation of bleeding risk in atrial fibrillation and venous thromboembolism: executive summary of a European and Asia-Pacific expert consensus paper. Thromb Haemost 2022; 122 (10) 1625-1652
23 Goto S, Goto S. Dual antiplatelet (DAPT) or dual pathway inhibition (DPI). Thromb Haemost 2023; (e-pub ahead of print).
24 Kim HK, Tantry US, Smith Jr SC. et al. The East Asian paradox: an updated position statement on the challenges to the current antithrombotic strategy in patients with cardiovascular disease. Thromb Haemost 2021; 121 (04) 422-432
25 Gorog DA, Jeyalan V, Markides RIL, Navarese EP, Jeong YH, Farag M. Comparison of de-escalation of DAPT intensity or duration in East Asian and Western patients with ACS undergoing PCI: a systematic review and meta-analysis. Thromb Haemost 2023; 123 (08) 773-792
26 Ortega-Paz L, Franchi F, Rollini F. et al. Switching from dual antiplatelet therapy with aspirin plus a P2Y12 inhibitor to dual pathway inhibition with aspirin plus vascular-dose rivaroxaban: the Switching Anti-Platelet and Anti-Coagulant Therapy (SWAP-AC) study. Thromb Haemost 2023 (e-pub ahead of print)
27 Birocchi S, Rocchetti M, Minardi A, Podda GM, Squizzato A, Cattaneo M. Guided anti-P2Y12 therapy in patients undergoing PCI: three systematic reviews with meta-analyses of randomized controlled trials with homogeneous design. Thromb Haemost 2023; (e-pub ahead of print).
28 Landolina D, Ammirabile N, Capodanno D. Strategies for tailored antiplatelet therapy after percutaneous coronary intervention: unraveling complexities, embracing nuances. Thromb Haemost 2023
29 Stefanini L, Ruberto F, Curreli M. et al. Increased von Willebrand factor platelet-binding capacity is related to poor prognosis in COVID-19 patients. Thromb Haemost 2023; 123 (01) 118-122
30 Giannis D, Goldin M, Rahman H. et al. Risk factors for postdischarge major thromboembolism and mortality in hospitalized patients with COVID-19 with cardiovascular comorbidities: insights from the CORE-19 registry. Thromb Haemost 2023; 123 (11) 1089-1099
31 Rolling CC, Sowa MA, Wang TT. et al. P2Y12 inhibition suppresses proinflammatory platelet-monocyte interactions. Thromb Haemost 2023; 123 (02) 231-244
32 Talasaz AH, Sadeghipour P, Bakhshandeh H. et al. Atorvastatin versus placebo in ICU patients with COVID-19: ninety-day results of the INSPIRATION-S trial. Thromb Haemost 2023; 123 (07) 723-733
33 Tu W-J, Xu Y, Liu Y, Li J, Du J, Zhao J. Intravenous thrombolysis or medical management for minor strokes. Thromb Haemost 2023; 123 (07) 734-743
34 Cameron AC, Abdul-Rahim AH. The optimal management for people with acute stroke and minor deficits: intravenous thrombolysis or medical management?. Thromb Haemost 2023; 123 (07) 666-668
35 Duarte-Gamas L, Jácome F, Dias LR. et al. Catheter-directed thrombolysis protocols for deep venous thrombosis of the lower extremities-a systematic review and meta-analysis. Thromb Haemost 2023; (e-pub ahead of print).
36 Barnes GD, Obi AT. Catheter-directed thrombolysis for deep vein thrombosis: serving at break point. Thromb Haemost 2023; (e-pub ahead of print).
37 Becattini C, Agnelli G, Maggioni AP. et al; COPE Investigators. Contemporary management and clinical course of acute pulmonary embolism: the COPE study. Thromb Haemost 2023; 123 (06) 613-626
38 Hwang HG, Lee JH, Bang SM. Incidence of pregnancy-associated venous thromboembolism: second nationwide study. Thromb Haemost 2023; 123 (09) 904-910
39 Tsai C-T, Chao T-F. Incidence and risk factors for pregnancy-associated venous thromboembolism: are there differences between east and west?. Thromb Haemost 2023; 123 (09) 911-912
40 Grandone E, Antonucci E, Colaizzo D. et al. Venous thromboembolism in women of childbearing age: insights from the START registry. Thromb Haemost 2023; 123 (11) 1060-1068
41 Xu K, Chan NC. Risk factors for venous thromboembolism in women of childbearing age. Thromb Haemost 2023; 123 (11) 1069-1071
42 Goualou M, Noumegni S, de Moreuil C. et al. Venous thromboembolism associated with assisted reproductive technology: a systematic review and meta-analysis. Thromb Haemost 2023; 123 (03) 283-294
43 Grandone E, Ageno W. The legacy of Edwards and Steptoe and the windy roads of assisted reproduction: where do we stand with venous thromboembolism?. Thromb Haemost 2023; 123 (03) 267-269
44 Corica B, Lobban T, True Hills M. et al. Sex as a risk factor for atrial fibrillation-related stroke. Thromb Haemost 2023; (e-pub ahead of print).
45 Frischmuth T, Tøndel BG, Brækkan SK. et al. The risk of incident venous thromboembolism attributed to overweight and obesity: the Tromsø Study. Thromb Haemost 2023 (e-pub ahead of print)
46 Wang J, Tan J, Hua L, Sheng Q, Huang X, Liu P. Genetic predisposition of both waist circumference and hip circumference increased the risk of venous thromboembolism. Thromb Haemost 2023; 123 (03) 347-361
47 Gaugler JO, Righini M, Robert-Ebadi H. et al. Obesity as a predictor for pulmonary embolism and performance of the age-adjusted D-dimer strategy in obese patients with suspected pulmonary embolism. Thromb Haemost 2023; (e-pub ahead of print).
48 Goldhaber SZ. Obesity and pulmonary embolism: can we dismantle the “obesity paradox”. Thromb Haemost 2023
49 Martin KA, Zakai NA. Venous thromboembolism and obesity: moving toward a better understanding of the population-attributable risk. Thromb Haemost 2023; (e-pub ahead of print).
50 Roberge G, Samson C, Le Gal G, Calabrino A. Prolonged fasting as a cause of deep vein thrombosis: a case report. TH Open 2023; 7 (02) e94-e96
51 McIntyre W, Collaborators ASAE. AF SCREEN and AFFECT-EU Collaborators. Protocol for a systematic review and individual participant data meta-analysis of randomized trials of screening for atrial fibrillation to prevent stroke. Thromb Haemost 2023; 123 (03) 366-376
52 Ryu J-C, Bae J-H, Ha SH. et al. Hypercoagulability on thromboelastography can predict the functional outcomes in patients with acute ischemic stroke. Thromb Haemost 2023; 123 (12) 1180-1186
53 Paciaroni M. Hypercoagulability state in predicting severe functional outcome in patients with acute ischemic stroke: cause, consequence, or both?. Thromb Haemost 2023; 123 (12) 1187-1189
54 le Sève JD, Guédon AF, Bordenave S. et al. Risk factors of venous thromboembolic disease in cancer patients treated with immune checkpoint inhibitor. Thromb Haemost 2023; 123 (11) 1049-1056
55 Khorana AA. Immune checkpoint inhibitors and venous thromboembolism: the more things change…. Thromb Haemost 2023; 123 (11) 1057-1059
56 McBane Ii RD, Vlazny DT, Houghton D. et al. Survival implications of thrombus recurrence or bleeding in cancer patients receiving anticoagulation for venous thromboembolism treatment. Thromb Haemost 2023; 123 (05) 535-544
57 Xu K, Chan NC. Recurrent thrombosis and bleeding in patients with cancer-associated venous thromboembolism receiving anticoagulation: are these modifiable risk factors for mortality?. Thromb Haemost 2023; 123 (05) 487-489
58 Cohen AT, Wallenhorst C, Choudhuri S, Nassar A, Pollock KG, Martinez C. A novel risk prediction score for clinically significant bleeding in patients anticoagulated for venous thromboembolism with active cancer. Thromb Haemost 2023; (e-pub ahead of print).
59 Roldán V, Soler-Espejo E, Marin F. Predicting bleeding in cancer-associated venous thromboembolism: another milestone achieved. Thromb Haemost 2023; (e-pub ahead of print).
60 Rønnow Sand J, Troelsen FS, Nagy D. et al. Increased cancer risk in patients with kidney disease and venous thromboembolism: a population-based cohort study. Thromb Haemost 2023; 123 (12) 1165-1176
61 Konstantinides SV. Kidney disease and cancer risk in patients with venous thromboembolism: what does it mean for clinical practice?. Thromb Haemost 2023; 123 (12) 1177-1179
62 Caroti KS, Becattini C, Carrier M. et al. Rivaroxaban versus apixaban for treatment of cancer-associated venous thromboembolism in patients at lower risk of bleeding. TH Open 2023; 7 (03) e206-e216
63 Sigüenza P, López-Núñez JJ, Falgá C. et al; RIETE Investigators. Enoxaparin for the long-term therapy of venous thromboembolism in patients with cancer and renal insufficiency. Thromb Haemost 2023; (e-pub ahead of print).
64 Trzepizur W, Gervès-Pinquié C, Heudes B. et al; Pays de la Loire Cohort Study Group. Sleep apnea and incident unprovoked venous thromboembolism: data from the Pays de la Loire sleep cohort. Thromb Haemost 2023; 123 (04) 393-401
65 Bikdeli B, Lo Y-C, Khairani CD. et al. Developing validated tools to identify pulmonary embolism in electronic databases: rationale and design of the PE-EHR+ study. Thromb Haemost 2023; 123 (06) 649-662
66 Squizzato A, Venturini A, Pelitti V. et al. Diagnostic accuracy of V/Q and Q SPECT/CT in patients with suspected acute pulmonary embolism: a systematic review and meta-analysis. Thromb Haemost 2023; 123 (07) 700-713
67 Konstantinides S. Modern lung scintigraphy techniques for optimizing the diagnosis of pulmonary embolism: great expectations still awaiting to be met. Thromb Haemost 2023; 123 (07) 663-665
68 Pedersen OB, Grove EL, Nissen PH. et al. Expression of microRNA predicts cardiovascular events in patients with stable coronary artery disease. Thromb Haemost 2023; 123 (03) 307-316
69 Liu X, Li X, Xiong S. et al. Neutrophil extracellular traps: potential prothrombotic state markers and therapeutic targets for atrial fibrillation. Thromb Haemost 2023; (e-pub ahead of print).
70 Wang G, Abrams ST, Toh C-H. Are NETs a novel, exciting, thrombosis risk marker?. Thromb Haemost 2023; (e-pub ahead of print).
71 Lahu S, Adler K, Mayer K. et al. Plasma soluble glycoprotein VI, platelet function, bleeding, and ischemic events in patients undergoing elective percutaneous coronary intervention. Thromb Haemost 2023; (e-pub ahead of print).
72 Harm T, Frey M, Dittrich K. et al. Statin treatment is associated with alterations in the platelet lipidome. Thromb Haemost 2023; 123 (06) 585-596
73 Goto S, Goto S. Statin treatment and the alterations in the platelet lipidome: what is the impact of lipid profile on thrombosis?. Thromb Haemost 2023; 123 (06) 573-575
74 Chen D, Zhao Z, Liu P. et al. Adventitial vasa vasorum neovascularization in femoral artery of type 2 diabetic patients with macroangiopathy is associated with macrophages and lymphocytes as well as the occurrence of cardiovascular events. Thromb Haemost 2023; 123 (10) 989-998
75 Badimon L, Arderiu G. Atherosclerotic plaque VASA vasorum in diabetic macroangiopathy: WHEN IS important, but also HOW IS needed. Thromb Haemost 2023; 123 (10) 999-1002
76 Bianchini M, Möller-Ramon Z, Weber C, Megens RTA, Duchêne J. Short-term western diet causes rapid and lasting alterations of bone marrow physiology. Thromb Haemost 2023; 123 (11) 1100-1104
77 Sachetto ATA, Mackman N. Monocyte tissue factor expression: lipopolysaccharide induction and roles in pathological activation of coagulation. Thromb Haemost 2023; 123 (11) 1017-1033
78 Bongiovanni D, Novelli L, Condello F. et al. Reticulated platelets predict cardiovascular death and adverse events in coronary artery disease: a systematic review and meta-analysis. Thromb Haemost 2023; (e-pub ahead of print).
79 Esteve-Pastor MA, Soler-Espejo E, Marín F. Reticulated platelets: a promising prognosis marker in cardiovascular diseases. Thromb Haemost 2023; (e-pub ahead of print).
80 Kawano T, Hisada Y, Grover SP. et al. Decreased platelet reactivity and function in a mouse model of human pancreatic cancer. Thromb Haemost 2023; 123 (05) 501-509
81 Gui X, Chu X, Du Y. et al. Impaired platelet function and thrombus formation in PDE5A-deficient mice. Thromb Haemost 2023; 123 (02) 207-218
82 Seidizadeh O, Ciavarella A, Baronciani L. et al. Clinical and laboratory presentation and underlying mechanism in patients with Low VWF. Thromb Haemost 2023; (e-pub ahead of print).
83 Nagy Z, Nieswandt B. PDE5A: key enzyme to overcome platelet inhibition. Thromb Haemost 2023; 123 (02) 131-132
84 Bourne JH, Smith CW, Jooss NJ. et al. CLEC-2 supports platelet aggregation in mouse but not human blood at arterial shear. Thromb Haemost 2022; 122 (12) 1988-2000
85 McFadyen JD, Mangin PH, Peter K. Of mice and man: the unwinding of CLEC-2 as an antithrombotic target?. Thromb Haemost 2022; 122 (12) 1963-1965
86 Machado SK, Peil H, Kraushaar T. et al. Modulation of extravascular binding of recombinant factor IX impacts the duration of efficacy in mouse models. Thromb Haemost 2023; 123 (08) 751-762
87 Pilch J, Knowles LM. Extravascular binding of coagulation factor IX gives hemostasis a boost. Thromb Haemost 2023; 123 (08) 750
88 Souri M, Yokoyama C, Osaki T, Ichinose A. Antibodies against noncatalytic B subunit of factor XIII inhibit activation of factor XIII and fibrin crosslinking. Thromb Haemost 2023; 123 (09) 841-854
89 Katona É. Functional consequences of antibodies against noncatalytic B Subunit of factor XIII. Thromb Haemost 2023; 123 (09) 855